Loading...
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer
Histone deacetylase inhibitors (HDACis) are a new class of anticancer drugs confirmed to have good therapeutic effects against gastric cancer (GC) in preclinical experiments, but most HDACis are non-selective (pan-HDACis), with highly toxic side effects. Therefore, it is necessary to screen HDAC fam...
Saved in:
| Published in: | Exp Mol Med |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group UK
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6802628/ https://ncbi.nlm.nih.gov/pubmed/31451695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s12276-019-0301-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|